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Abstract 
Background: To date, research findings are inconsistent about whether neuroanatomy in transgender 
persons resembles that of their natal sex or their gender identity. Moreover, few studies have examined 
the effects of long-term, cross-sex hormonal treatment on neuroanatomy in this cohort. The purpose of 
the present study was to examine neuroanatomical differences in transgender persons after prolonged 
cross-sex hormone therapy.  
Methods: Eighteen transgender men (female-to-male), 17 transgender women (male-to-female), 30 
non-transgender men (natal men), and 27 non-transgender women (natal women) completed a high-
resolution structural MRI scan at 3Tesla. Eligibility criteria for transgender persons were gender 
affirming surgery and at least 2 years of cross-sex hormone therapy. Exclusion criteria for non-
transgender persons were presence of psychiatric or neurological disorder.  
Results: Mean neuroanatomical volume for the amygdala, putamen and corpus callosum differed 
between transgender women and natal women but not between transgender women and natal men. 
Differences between transgender men and natal men were found in several brain structures, including 
the medial temporal lobe structures and cerebellum. Differences between transgender men and natal 
women were found in the medial temporal lobe, nucleus accumbens, and 3rd ventricle. Sexual 
dimorphism between non-transgender men and women included larger cerebellar volumes and smaller 
anterior corpus callosum in natal men relative to natal women. The results remained stable after 
correcting for additional factors including age, total intracranial volume, anxiety, and depressive 
symptoms.  
Conclusions: Neuroanatomical differences were region-specific between transgender persons and 
their natal sex as well as their gender identity suggesting localized influence of sex hormones on 
neuroanatomy.   
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Introduction 
Sexual dimorphism is widespread in the brain. Such dimorphism suggests for example that cerebellar, 
putamen, amygdala, and hippocampal volumes are larger in men versus women, whereas women have 
larger thalamic nuclei, lateral frontal gyri, and insular cortices than men [1]. However, the relationship 
between brain structure and gender identity is less clear. Presently, findings are inconsistent about 
whether the neuroanatomy of transgender persons resembles that of their natal sex or their gender 
identity (for recent review see [2]). One central question that remains to be determined is whether 
cross-sex hormone treatment “reverses” neuroanatomical sexual dimorphism, resulting in 
neuroanatomical features characteristic of gender identity rather than natal sex. Currently, however, 
studies on the neuroanatomical changes in transgender persons after prolonged cross-sex hormone 
treatment are too few in number to examine the putative effects of hormone therapy on neuroanatomy.  
A post-mortem study in a small sample of hormonally-treated transgender women (TW, male-
to-female) found that the bed nucleus of the stria terminalis [3] was similar in size to that typically 
found in non-transgender females, an effect that might have been partly driven by cross-sex hormone 
exposure. More recent studies evaluated the effects of testosterone treatment in transgender men (TM, 
female-to-male) and estrogen and antiandrogen treatment in TW [4-6]. Although one of these studies 
found cortical thickness was more characteristic of participants’ gender identity than their natal sex in 
TM receiving androgens and TW receiving antiandrogens and estrogens [4], the findings contradict a 
study with an opposite pattern of cortical thickness in non-treated TW in the same areas [7]. Likewise, 
although one study reported a decrease in hypothalamus volume in TW with no changes in TM after 
treatment [5], another [6] cross-sex hormone study documented increases in TM in this region. 
Moreover, findings in transgender persons before they received hormone treatment are also difficult to 
interpret. Such studies have documented either a larger [8] or a smaller [9] putamen volume in TW 
relative to that of natal men, and some studies [10] could not find differences in other sexually 
dimorphic structures such as the corpus callosum [11]. Thus, current findings are inconsistent, and 
more complementary and confirmatory evidence is needed.  
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Despite the small number of structural MRI studies in transgender persons, parallel 
neuroimaging work in endocrine conditions of gonadal hormone perturbations might aid in predicting 
which brain regions are sensitive to sex steroid fluctuations [12-15]. The commonly found larger 
amygdala and hippocampal volumes in males relative to females are reduced in androgen deficiency 
[15]. Likewise, both androgen deficiency in Klinefelter Syndrome patients and antiandrogen treatment 
in TW appear to reduce cortical thickness in temporal cortex and increase ventricle size [4, 5, 14]. 
Finally, similar to striatal changes in transgender persons [8, 9], boys with early androgen excess have 
larger putamen volume and an enlarged medial temporal lobe (MTL) relative to unaffected 
comparisons [16]. Taken together, these converging lines of evidence indicate sensitivity to sex 
hormone fluctuations in several regions including the medial temporal lobe (MTL), the striatum, and 
the ventricles. However, data regarding specific associations of these structures with hormonal 
treatment in transgender persons are scarce.!
This study examined whether the neuroanatomy in transgender persons receiving cross-sex 
hormone therapy resembled that of their natal sex or their gender identity in regions sensitive to 
gonadal hormone fluctuations. Additionally, global brain changes including total and subcortical grey 
matter volume (GMV), cerebellum, and corpus callosum size were also examined. To this end, we 
used a comprehensive morphometric analysis, analyzing not only volume but also cortical thickness 
and surface area. Based on the limited evidence available [4, 6-9, 16], we hypothesized patterns 
consistent with gender identity rather than natal sex in transgender persons.!
 
****************************** Table 1 about here please******************* 
 
 
Methods 
Participants 
Eighteen transgender men (TM, M age = 37.22 years, SD = 8.29), 17 transgender women (TW, M age 
= 41.47, SD = 6.86), 27 non-transgender women (NTW, M age = 32.63, SD = 10.02) and 30 non-
transgender men (NTM, M age = 31.50, SD = 8.52) participated in the study. Originally, another 7 
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participants were recruited but had to be excluded due to missing values on the anxiety and depression 
questionnaires. All transgender participants had undergone gender affirming surgery and been 
receiving cross-sex hormone therapy for at least 2 years. Thus, the final sample consisted of 92 
participants in total (Table1). The sample differed significantly in age (F(3,88) = 5.82, p = .001) as 
well as depression (F(3,88) = 6.32, p=.001) and trait anxiety (F(3,88)= 4.14, p=.009). Age, depression, 
and trait anxiety were consequently used as covariates of no interest in all subsequent analyses. 
Transgender persons were recruited through flyers and the Department of Endocrinology of Ghent 
University Hospital and scanned on a 3T Siemens Trio (Siemens, Erlangen, Germany) MRI Scanner 
on site. Comparison participants were recruited through word of mouth and flyers. Exclusion criteria 
were present neurological or psychiatric disorders, or usage of psychotropic medication. The study 
was approved by the Medical Ethical Committee of Ghent University Hospital. All participants signed 
an informed consent prior to the study.   
 
Screening questionnaires 
Previous studies have acknowledged presence of mood and anxiety problems in transgender persons 
[17]. To be able to covary for potential differences in depression or anxiety, all participants completed 
the Beck Depression Inventory (BDI, [18]) and the Spielberger State/Trait Anxiety Inventory (STAI, 
[19]).  
 
MRI acquisition 
A high-resolution T1-weighted MPRAGE anatomical image was acquired (duration = 5:14 min) in 
ascending order with a FOV = 256 mm2, slice thickness 1 x 1 x1 mm, TR = 2250 ms, TE = 2.52 ms, 
flip angle = 9 deg.  
 
MRI processing and analysis 
The original images were first visually inspected for artifacts and abnormal clinical findings that 
would lead to exclusion. Data were analysed with freesurfer (release 4.3.0, Martinos Center for 
Biomedical Imaging, Charlestown, MA; http://surfer.nmr.mgh.harvard.edu, [20, 21]) using an 
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automated procedure. Briefly, images were registered to a common stereotaxic space using affine 
transforms, normalized with respect to intensity, and skull stripped. Quality control was performed on 
a semi-automated basis checking for outliers and visual inspection after each processing step.   
Structural neuroanatomy was characterized at three levels: 1) Grey matter volume (GMV) of 
subcortical brain structures, 2) cortical thickness, and 3) surface area size. Based on prior structural 
MRI findings [4, 7, 9, 22], and to reduce the chance of false positive findings, this study focused 
specifically on a priori regions of interest (ROIs), namely the MTL (amygdala, hippocampus, 
parahippocampus, fusiform gyrus) and the striatum (caudate nucleus, putamen, nucleus accumbens). 
In addition, major global volumetric effects (i.e., cortical and subcortical total GMV), cerebellum size, 
ventricle (3rd, 4th, 5th) size, and corpus callosum volume (anterior/middle/posterior) were also 
investigated. Data were analysed using SPSS V.21 (alpha = .05, two-tailed). Multivariate analysis of 
variance (MANOVA) were used with Group as the between-subjects factor (TM, TW, NTM, NTW) 
and the following covariates of no interest age, total intracranial volume (TICV), total depressive 
symptoms (BDI), total trait anxiety symptoms (STAI Trait). Of note, given that total intracranial 
volume was covaried for, all differences in size have to be interpreted as being relative rather than 
absolute. To correct for multiple comparison testing, follow-up tests of significant effects were 
corrected using a step-down Bonferroni (Holm) procedure, p < .05corrected, two tailed. To provide a 
more comprehensive picture of the results than normally given by p-values, upper and lower limits of 
the 95% CI are also presented in the tables [23]. 
 
****************************** Table 2 about here please******************* 
 
Results 
Medial temporal lobe (MTL) 
In MTL, a main effect of group was found for the left (F(3,84) = 3.68, p = .02) and right (F(3,84) = 
2.81, p =.045) amygdala. After correction, follow-up tests indicated a larger left amygdala volume for 
TW relative to NTW (pcorr. = .018). Follow-up tests in the right amygdala did not survive statistical 
correction. A main effect in the right fusiform gyrus volume (F(3,84) = 2.76, p = .047) revealed a 
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significantly smaller volume in TM relative to both NTW (pcorr. =0.048) and NTM (pcorr. = 
0.053)(Figure1). In addition, right fusiform area was also significantly different among the groups 
(F(3,83) = 4.74, p = .004). Here, NTM and NTW relative to TM had a larger surface area (pcorr. =.042 
and pcorr. = 0.06, respectively). A main effect of group in the right parahippocampal area (F(3,84) = 
3.08, p =.03) did not result in significant effects after correction. !
 
 
****************************** Table 3 about here please******************* 
****************************** Figure 1 about here please******************* 
 
Striatum  
In the striatum, a significant effect of group was found in the right putamen volume (F(3,84) = 3.63, p 
= .02) indicating larger volume for TW relative to NTW (pcorr. = .042). No other effect survived 
correction. Follow-up tests to a main effect in the right accumbens (F(3,84) = 2.68, p = .05) indicated 
larger volume in TM relative to NTW (pcorr. = .024)(Figure 1, Table 3).  
 
 
****************************** Table 4 about here please******************* 
 
 
Global effects  
Global analyses revealed significant group differences in the left (F(3,84) = 5.34, p=.002) and right 
(F(3,84) = 5.67, p = .001) cerebellum. Specifically, in the left cerebellum, corrected follow-up tests 
indicated larger relative left cerebellar volume in NTM relative to NTW (pcorr. = .006) and TM (pcorr. = 
.02). The same effect was present for the right cerebellum showing larger volume in NTM relative to 
NTW (pcorr. = .006) and TM (pcorr. = .006)(Table 4). A group effect in the anterior corpus callosum 
(F(3,83) = 4.70, p = .004) indicated that this region was larger in NTW than NTM (pcorr. = .045) and 
TW (pcorr. < .001). A similar effect in the posterior corpus callosum (F(3,83) = 3.40, p = .02)(Figure1) 
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revealed larger volume for NTW and TM than TW (pcorr. = .01 for both comparisons). A different 
pattern was observed for the 3rd ventricle (F3,84) = 3.99, p = .01). It was smaller 3rd in TM relative to 
TW (pcorr.  = .035) and NTW (pcorr. = .03)(Table 4). !
 
 
In summary, neuroanatomical differences between transgender women and non-transgender women 
were found in the left amygdala, right putamen, and anterior/posterior corpus callosum. No differences 
were found in any measure between transgender women and non-transgender men. Differences 
between transgender men and non-transgender men were detected in fusiform gyrus volume and 
surface area, and the cerebellum. Transgender men differed from non-transgender women in right 
accumbens and fusiform gyrus volume/surface area, and 3rd ventricle size. Transgender men differed 
from transgender women in posterior corpus callosum. Sexually dimorphic effects indicated larger 
cerebellar volumes in natal men relative to natal women but a larger anterior corpus callosum for natal 
women.   
 
 
Discussion!
The present study examined differences in neuroanatomy between cross-sex hormone treated 
transgender men and transgender women. Based on prior work in transgender persons [4, 6, 8, 9] and 
in patients who had endocrine conditions with gonadal hormone perturbations [12, 15, 16], group 
differences were expected in the MTL, striatum, and ventricles. Three main findings pertinent to the 
study hypotheses were found: 1) Consistent with their natal sex, TW did not differ from non-
transgender men and showed differences relative to non-transgender women in corpus callosum, 
putamen, and amygdala, 2) Consistent with their gender identity, transgender men differed from non-
transgender women in the 3rd ventricle and the nucleus accumbens, 3) Transgender men differed from 
both natal men and natal women in fusiform volume. 
Much of the brain is sexually dimorphic, especially the MTL given 1) larger amygdala and 
hippocampus volume in men relative to women [1], 2) high sex steroid receptor density in the MTL 
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[24], and 3) volumetric alterations of these structures in endocrine conditions of gonadal hormone 
perturbations [12]. To date, findings in transgender persons are highly inconsistent. Whereas some [9] 
have documented altered hippocampal volumes in transgender women before hormone treatment, 
others [4] could not replicate this effect. Associations in the present study indicated that amygdala 
volume in transgender women was consistent with the their natal sex rather than their gender identity. 
However, one surprising finding was that volume and area size in the fusiform gyrus were smaller in 
transgender men relative to both NTM and NTW, a finding that has not been reported previously. By 
comparison, no group differences were present in the hippocampus. Thus, although some differences 
might exist pre-treatment [9], the present findings and those of others [4] indicate that the amygdala 
and hippocampus volumes do not reverse to mirror gender identity after hormone treatment.  
Based on prior work in endocrine conditions [16] and transgender persons [4], we had also 
hypothesized significant group differences in the striatum. Prior work has noted volumetric differences 
in the dorsal striatum (putamen) in transgender persons [8, 9] and endocrine disorders of androgen 
excess [16] albeit with mixed results to date. Whereas Savic & Arver [9] reported reduced putamen 
volume in TW relative to NTM and NTW, the opposite finding, namely a larger putamen in TW 
relative to NTM was found by Luders and colleagues [8]. The present finding of larger putamen 
volume in TW relative to NTW is thus largely consistent with that latter study. Given that the 
participants in the study by Luders et al. were transgender women who had not received hormone 
treatment and our participants were already receiving hormones for more than 2 years, the current data 
suggest that the putamen effect is stable and does also not change with cross-sex hormone therapy. 
Instead it might indicate pre-existing group differences. One interesting, previously not reported, 
association concerned the ventral striatum, i.e., the nucleus accumbens. Here, TM showed an effect 
consistent with their gender identity rather than their natal sex. !
Finally, the present study also revealed associations between gender identity and global 
volumetric effects. Previous studies have documented larger ventricles in transgender women [4] but 
reductions in transgender men after cross-sex hormone therapy [5]. Consistent with the latter 
investigation [5], transgender men in the present study also had significantly smaller 3rd ventricles with 
no differences in 4th or 5th ventricles relative to both transgender women and non-transgender women. 
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In agreement with their suggestion [5], such a ventricular change might be due to a volumetric change 
in the structures surrounding the 3rd ventricle. Although further consistent with a sexually dimorphic 
pattern [11], the larger corpus callosum in TM and NTW relative to TW and NTM would indicate no 
change in this structure with cross-sex hormone treatment. Supplementing this finding, prior work to 
date has failed to identify differences in pre-hormone treated transgender persons in this structure [10]. 
Therefore, although 3rd ventricle size may be sensitive to hormonal treatment in transgender men, the 
corpus callosum does not appear to be responsive indicating regional sensitivity to hormone therapy.  
The precise clinical relevance of neuroanatomical changes after hormone therapy remains to 
be determined. However, characterizing the different changes associated with cross-sex hormone 
treatment is important. For example, ventricular enlargement has not only been associated with grey 
matter reduction due to ageing [26], but has also been identified as a putative marker for progression 
of Alzheimer’s Disease [27] or a risk factor for psychopathology [28]. Hulshof Pol [5] observed a final 
3rd ventricle size in transgender women on hormonal therapy that was larger after treatment than the 
ventricle size observed in both natal men and women. Although the mechanisms and clinical 
implications of such effects are unknown, they deserve further study given reports of physiological 
risk with hormonal treatment [25] and prevalence of psychopathology [17] in transgender persons. 
Much more complementary information on the physiological and neurological changes with hormonal 
treatment is therefore needed. !
Some limitations of the present study require discussion. First, the relatively small sample size 
of patients needs to be acknowledged. However, the sample size of the present study was within the 
range of prior work (e.g., [4, 8, 10, 22]). The second limitation concerns the fact that although all 
participants had received gender affirming surgery and had already been taking cross-sex hormone 
therapy for a minimum of 2 years, MRI scans from before the genital surgery were lacking. Thus, we 
cannot make any statements regarding causality of treatment and merely report associations. However, 
we nonetheless believe these data worthwhile to be reported for the following reasons. First, with the 
exception of four prior studies, three in-vivo [4-6]) and one post-mortem [3], the majority of earlier 
morphometric work has examined structural brain differences in transgender persons who had not 
received hormone treatment. Moreover, these prior studies were characterized by relatively small 
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sample size requiring independent replication. Second, our study included both TM and TW whereas a 
few prior studies only included TW [3, 7-9] or TM [6] thus enabling a more comprehensive 
comparison. Third, in the present study, subthreshold mood and anxiety symptoms were taken into 
consideration. This has not been examined in prior work although it may have played an important 
role in their findings. Although it could be criticized that such differences in mood and anxiety only 
occurred in our sample, we believe this to be unlikely given convincing documentation of depressive 
and anxious symptoms in transgender persons [17]. This would suggest that our sample is 
representative of transgender persons living in their gender identity. Fourth and finally, direct sex 
differences between natal men and natal women were few and limited to the cerebellum and the 
corpus callosum. However, due to the large variability among the population, large-scale studies 
(e.g.,[1, 11]) are needed to make definitive statements. Therefore, the findings should be considered 
relative to the transgender groups rather than displaying a lack of normal sexual dimorphism.  
Broadly speaking, the findings of the present study are largely consistent with prior work [4-6] 
in that they suggest some plasticity of the brain even during adulthood with cross-sex hormone 
treatment. However, they also appear to indicate regionally-specific changes, such that some, but not 
all, investigated structures transition towards gender identity.  Future studies are needed to replicate 
these findings and examine in a next step whether these neuroanatomical differences are associated 
with functional or cognitive changes of the subserved brain regions.  
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Captions 
Figure 1. Figure displays mean and 95% CI of the volumetric analyses for the four groups. Horizontal 
lines indicate significant differences (p<.05corr) between groups after correction for multiple 
comparisons. 
 
Table 1. Demographic information for each of the four groups, comparison men (CM), comparison 
women (CW), trans men (TM), trans women (TW).  
 
Table 2. Results of morphometric analyses for each of the groups in the medial temporal lobe. Results 
are mean values with the 95% CI in square brackets underneath. For volume, values are mm3 for area 
they are mm2 and for thickness are mm.   
 
Table 3. Results of morphometric analyses of the striatum for each of the groups. Results are mean 
values with the 95% CI in square brackets underneath. Volumetric values are mm3.  
 
Table 4. Results of global volumetric analyses for each of the groups. Results are mean values with 
the 95% CI in square brackets underneath. Values are mm3.  
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